A valid prescription requires a telehealth consultation with a prescriber. No medication is dispensed without clinical evaluation.
Tirzepatide
Dual GLP-1 / GIP Incretin Agonist
Compound Specifications
Tirzepatide
Dual GLP-1 / GIP Incretin Agonist
Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor co-agonist. In clinical trials, simultaneous activation of both incretin pathways demonstrated body weight reduction and improvements in glycemic and metabolic markers.
This compounded tirzepatide formulation is not FDA-approved and has not been reviewed by FDA for safety, effectiveness, or manufacturing quality. Individual results may vary.
Tirzepatide acts through GIP and GLP-1 receptor pathways involved in glucose regulation, appetite signaling, and metabolic physiology.
Important Safety Information
Important Safety Information: Tirzepatide therapy requires individualized medical evaluation. A licensed provider will review medical history, current medications, contraindications, potential adverse effects, and other clinical factors before prescribing. Seek urgent medical attention for severe or life-threatening symptoms.
Report suspected adverse reactions to your provider and to FDA MedWatch at 1-800-FDA-1088 or fda.gov/medwatch.
Clinical Evidence for Tirzepatide
Clinical outcomes referenced on this page are based primarily on studies of FDA-approved tirzepatide products and do not establish identical outcomes for compounded formulations.
Administered once weekly subcutaneously, titrated under physician direction according to clinical response and tolerance.
Related Treatments & Resources
Frequently Asked Clinical Questions
Why is Tirzepatide preferred over single GLP-1s?
The dual GIP/GLP-1 mechanism is studied in clinical trials for its effects on metabolic markers and body weight.
Where is Tirzepatide compounded?
All preparations are prepared and dispatched from licensed U.S. compounding pharmacies pursuant to a valid prescription.